BIROn - Birkbeck Institutional Research Online

    Leflunomide treatment does not protect neural cells following Oxygen-Glucose Deprivation (OGD) in vitro

    Curel, Claire J.M. and Nobeli, Irene and Thornton, C. (2024) Leflunomide treatment does not protect neural cells following Oxygen-Glucose Deprivation (OGD) in vitro. Cells 13 (7), p. 631. ISSN 2073-4409.

    [img]
    Preview
    Text
    cells-13-00631.pdf - Published Version of Record
    Available under License Creative Commons Attribution.

    Download (1MB) | Preview

    Abstract

    Neonatal hypoxia-ischemia (HI) affects 2–3 per 1000 live births in developed countries and up to 26 per 1000 live births in developing countries. It is estimated that of the 750,000 infants experiencing a hypoxic-ischemic event during birth per year, more than 400,000 will be severely affected. As treatment options are limited, rapidly identifying new therapeutic avenues is critical, and repurposing drugs al- ready in clinical use offers a fast-track route to clinic. One emerging avenue for therapeutic intervention in neonatal HI is to target mitochondrial dysfunction, which occurs early in the development of brain injury. Mitochondrial dynamics are particularly affected, with mitochondrial fragmentation occurring at the expense of the pro-fusion protein Optic Atrophy (OPA)1. OPA1, together with mitofusins (MFN)1/2, are required for membrane fusion, and therefore, protecting their function may also safeguard mitochon- drial dynamics. Leflunomide, an FDA-approved immunosuppressant, was recently identified as an acti- vator of MFN2 with partial effects on OPA1 expression. We, therefore, treated C17.2 cells with Lefluno- mide before or after oxygen-glucose deprivation, an in vitro mimic of HI, to determine its efficacy as a neuroprotection and inhibitor of mitochondrial dysfunction. Leflunomide increased baseline OPA1 but not MFN2 expression in C17.2 cells. However, Leflunomide was unable to promote cell survival follow- ing OGD. Equally, there was no obvious effect on mitochondrial morphology or bioenergetics. These data align with studies suggesting that the tissue and mitochondrial protein profile of the target cell/tissue are critical for taking advantage of the therapeutic actions of Leflunomide.

    Metadata

    Item Type: Article
    School: Birkbeck Faculties and Schools > Faculty of Science > School of Natural Sciences
    Depositing User: Irene Nobeli
    Date Deposited: 08 Apr 2024 15:43
    Last Modified: 09 Apr 2024 09:25
    URI: https://eprints.bbk.ac.uk/id/eprint/53351

    Statistics

    Activity Overview
    6 month trend
    11Downloads
    6 month trend
    89Hits

    Additional statistics are available via IRStats2.

    Archive Staff Only (login required)

    Edit/View Item Edit/View Item